|
1
|
Kiri S and Ryba T: Cancer, metastasis, and
the epigenome. Mol Cancer. 23:1542024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
3
|
de Visser KE and Joyce JA: The evolving
tumor microenvironment: From cancer initiation to metastatic
outgrowth. Cancer Cell. 41:374–403. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tuna M, Mills GB and Amos CI: The role of
long non-coding RNAs in lung cancer metastasis: Molecular
mechanisms, pathogenesis and clinical implications. Clin Transl
Med. 15:e704292025. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hwang ES, Reading J, Yu J, Dotto GP, Grady
WM, Czerniak B and Serrano M: Pre-cancer: From diagnosis to
intervention opportunities. Cancer Cell. 41:637–640. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang B, Hu H, Yu T, Tang W and Luo L:
VPS9D1-AS1: A critical oncogenic long non-coding RNA in human
malignancies. Clin Transl Oncol. 28:1998–2013. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yi Q, Zhu G, Zhu W, Wang J, Ouyang X, Yang
K and Zhong J: LINC00518: A key player in tumor progression and
clinical outcomes. Front Immunol. 15:14195762024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mosca N, Alessio N, Di Paola A, Marrapodi
MM, Galderisi U, Russo A, Rossi F and Potenza N: Osteosarcoma in a
ceRNET perspective. J Biomed Sci. 31:592024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Winkle M, El-Daly SM, Fabbri M and Calin
GA: Noncoding RNA therapeutics-challenges and potential solutions.
Nat Rev Drug Discov. 20:629–651. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li ML, Zhang Y and Ma LT: LncRNA HCG11
accelerates the progression of hepatocellular carcinoma via
miR-26a-5p/ATG12 axis. Eur Rev Med Pharmacol Sci. 23:10708–10720.
2019.PubMed/NCBI
|
|
11
|
Xu Y, Zheng Y, Liu H and Li T: Modulation
of IGF2BP1 by long non-coding RNA HCG11 suppresses apoptosis of
hepatocellular carcinoma cells via MAPK signaling transduction. Int
J Oncol. 51:791–800. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Zhang P, Wan X, Su X, Kong Z,
Zhai Q, Xiang X, Li L and Li Y: Downregulation of long non-coding
RNA HCG11 predicts a poor prognosis in prostate cancer. Biomed
Pharmacother. 83:936–941. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang L, Cao Y, Kou X, Che L, Zhou X, Chen
G and Zhao J: Long non-coding RNA HCG11 suppresses the growth of
glioma by cooperating with the miR-4425/MTA3 axis. J Gene Med.
21:e30742019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Y, Bao C, Zhang X, Lin X, Huang H and
Wang Z: Long non-coding RNA HCG11 modulates glioma progression
through cooperating with miR-496/CPEB3 axis. Cell Prolif.
52:e126152019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma J, Lang B, Xue L, Ding W and Tao S:
Long non-coding RNA HCG11 inhibits glioma cells proliferation and
migration through decoying miR-590-3p and up-regulating CADM2.
Pathobiology. 89:233–244. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang H, Huang H, Xu X, Wang H, Wang J,
Yao Z, Xu X, Wu Q and Xu F: LncRNA HCG11 promotes proliferation and
migration in gastric cancer via targeting miR-1276/CTNNB1 and
activating Wnt signaling pathway. Cancer Cell Int. 19:3502019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xie D, Li S, Wang X and Fang L: lncRNA
HCG11 suppresses cell proliferation in hormone receptor-positive
breast cancer via SRSF1/β-catenin. Aging (Albany NY). 15:179–192.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fan G, Jiao J, Shen F, Ren Q, Wang Q and
Chu F: Long non-coding RNA HCG11 sponging miR-522-3p inhibits the
tumorigenesis of non-small cell lung cancer by upregulating SOCS5.
Thorac Cancer. 11:2877–2886. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang G, Liu L, Zhang J, Huang C, Chen Y,
Bai W, Wang Y, Zhao K and Li S: LncRNA HCG11 suppresses cell
proliferation and promotes apoptosis via sponging miR-224-3p in
non-small-cell lung cancer cells. Onco Targets Ther. 13:6553–6563.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mao J, Qiu H and Guo L: LncRNA HCG11
mediated by METTL14 inhibits the growth of lung adenocarcinoma via
IGF2BP2/LATS1. Biochem Biophys Res Commun. 580:74–80. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang L, Zhou J, Zhang Y, Hu T and Sun Y:
Long non-coding RNA HCG11 aggravates osteosarcoma carcinogenesis
via regulating the microRNA-579/MMP13 axis. Int J Gen Med.
13:1685–1695. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gu J, Dai B, Shi X, He Z, Xu Y, Meng X and
Zhu J: lncRNA HCG11 suppresses human osteosarcoma growth through
upregulating p27 Kip1. Aging (Albany NY). 13:21743–21757. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xue HX, Li HF, Wang T, Li WJ and Bian WC:
LncRNA HCG11 suppresses laryngeal carcinoma cells progression via
sponging miR-4469/APOM axis. Eur Rev Med Pharmacol Sci.
24:3174–3182. 2020.PubMed/NCBI
|
|
24
|
Zheng J, Zhao Z, Ren H, Wang Y, Meng X,
Zhang W, Zhang C, Ming L and Lu X: LncRNA HCG11 facilitates
nasopharyngeal carcinoma progression through regulating
miRNA-490-3p/MAP3K9 axis. Front Oncol. 12:8720332022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Wang X, Luo H, Liu X, Huang J, Mi
Z, He S, Wen J, Gao Q, Yang H, et al: LncRNA HCG11 regulates
selinexor sensitivity in multiple myeloma. Biochem Pharmacol.
237:1169482025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo S, Song B, Li L, Li H, Yang T, Cao L
and Wang J: lncRNA HCG11 promotes colorectal cancer cell malignant
behaviors via sponging miR-26b-5p. J Immunol Res. 2023:90112322023.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cui Z, Wang Q, Deng MH and Han QL: LncRNA
HCG11 promotes 5-FU resistance of colon cancer cells through
reprogramming glucose metabolism by targeting the miR-144-3p-PDK4
axis. Cancer Biomark. 34:41–53. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu J, Xu W, Yang X, Liu Z and Sun Q:
LncRNA HCG11/miR-579-3p/MDM2 axis modulates malignant biological
properties in pancreatic carcinoma via Notch/Hes1 signaling
pathway. Aging (Albany NY). 13:16471–16484. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang YC, He WY, Dong CH, Pei L and Ma YL:
lncRNA HCG11 regulates cell progression by targeting miR-543 and
regulating AKT/mTOR pathway in prostate cancer. Cell Biol Int.
43:1453–1462. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Q, Yang K, Li J, Chen F, Li Y and
Lin Q: Long NONCODING RNA HCG11 acts as a tumor suppressor in
gastric cancer by regulating miR-942-5p/BRMS1 axis. J Oncol.
2021:99611892021.PubMed/NCBI
|
|
31
|
Li XF, Hu DM, Zhao YX, Zhang L and Jin Y:
Knockdown of lncRNA HCG11 suppresses cell progression in ovarian
cancer by modulating miR-144-3p/PBX3. Eur Rev Med Pharmacol Sci.
24:11032–11040. 2020.PubMed/NCBI
|
|
32
|
Chen X, Yang Y, Sun J, Hu C, Ge X and Li
R: LncRNA HCG11 represses ovarian cancer cell growth via AKT
signaling pathway. J Obstet Gynaecol Res. 48:796–805. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu Y, Tan X, Yang Q, Fang Z and Chen W:
LncRNA HCG11 enhances the chemosensitivity of non-small cell lung
cancer cells to Gemcitabine via miR-17-5p/p21 axis. Expert Rev
Anticancer Ther. 24:81–93. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yan H, Zhou Y, Chen Z, Yan X and Zhu L:
Long non-coding RNA HCG11 enhances osteosarcoma phenotypes by
sponging miR-1245b-5p that directly inhibits plakophilin 2.
Bioengineered. 13:140–154. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yan S and Wang M: HCG11 inhibits salivary
adenoid cystic carcinoma by upregulating EphA2 via binding to
miR-1297. Oral Surg Oral Med Oral Pathol Oral Radiol. 135:257–267.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Long R, Liu Z, Li J, Zhang Y and Yu H:
HCG11 up-regulation induced by ELK4 suppressed proliferation in
vestibular schwannoma by targeting miR-620/ELK4. Cancer Cell Int.
21:52021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu J, Li Y, Liu J and Xu Y:
Down-regulation of lncRNA HCG11 promotes cell proliferation of oral
squamous cell carcinoma through sponging miR-455-5p. J Gene Med.
23:e32932021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu L, Zhu Q, Chen S, Zhu H, Li C, Chen J
and Li X: Repurposing the bitter taste receptor TAS2R14 as a
pro-ferroptotic driver in thyroid cancer via the
STAT3-HCG11-miR-450b-5p axis. Acta Biochim Biophys Sin (Shanghai).
November 17–2025.(Epub ahead of print). View Article : Google Scholar
|
|
39
|
Wang R, Lv C, Li D, Song Y and Yan Z:
EEF1D stabilized by SRSF9 promotes colorectal cancer via enhancing
the proliferation and metastasis. Int J Cancer. 155:1487–1499.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mertens E, Keuchkarian M, Vasquez MS,
Vandevijvere S and Peñalvo JL: Lifestyle predictors of colorectal
cancer in European populations: A systematic review. BMJ Nutr Prev
Health. 7:183–190. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dai X, Chen W, Qiao Y, Chen X, Chen Y,
Zhang K, Zhang Q, Duan X, Li X, Zhao J, et al: Dihydroartemisinin
inhibits the development of colorectal cancer by GSK-3β/TCF7/MMP9
pathway and synergies with capecitabine. Cancer Lett.
582:2165962024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Alkharsan AMHMS, Safaralizadeh R,
Khalaj-Kondori M and HosseinpourFeizi M: Examination of the effects
of capecitabine treatment on the HT-29 colorectal cancer cell line
and HCG 11, HCG 15, and HCG 18 lncRNAs in CRC patients before and
after chemotherapy. Naunyn Schmiedebergs Arch Pharmacol.
398:6929–6940. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wedig J, Jasani S, Mukherjee D, Lathrop H,
Matreja P, Pfau T, D'Alesio L, Guenther A, Fenn L, Kaiser M, et al:
CD200 is overexpressed in the pancreatic tumor microenvironment and
predictive of overall survival. Cancer Immunol Immunother.
73:962024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Katoozian F, Abedi Kichi Z, Sharifi R and
Shirvani-Farsani Z: The expression analysis of long non-coding RNAs
related to Wnt/β-catenin signaling in pancreatic cancer patients.
Biochem Genet. 63:1605–1619. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jing S, Tian J, Zhang Y, Chen X and Zheng
S: Identification of a new
pseudogenes/lncRNAs-hsa-miR-26b-5p-COL12A1 competing endogenous RNA
network associated with prognosis of pancreatic cancer using
bioinformatics analysis. Aging (Albany NY). 12:19107–19128. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang X and Lu J: Immunotherapy for
hepatocellular carcinoma. Chin Med J (Engl). 137:1765–1776. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shi A, Liu L, Li S and Qi B: Natural
products targeting the MAPK-signaling pathway in cancer: Overview.
J Cancer Res Clin Oncol. 150:62024. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jacobson LEO, Bader-El-Den M, Maurya L,
Hopgood AA, Tamma V, Masum SK, Prendergast DJ and Osborn P:
Prostate MR image segmentation using a multi-stage network
approach. Int Urol Nephrol. 58:1201–1229. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Haghighi R, Castillo-Acobo RY, H Amin A,
Ehymayed HM, Alhili F, Mirzaei M, Mohammadzadeh Saliani S and
Kheradjoo H: A thorough understanding of the role of lncRNA in
prostate cancer pathogenesis; current knowledge and future research
directions. Pathol Res Pract. 248:1546662023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Weller M, Wen PY, Chang SM, Dirven L, Lim
M, Monje M and Reifenberger G: Glioma. Nat Rev Dis Primers.
10:332024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wu M, Wang T, Ji N, Lu T, Yuan R, Wu L,
Zhang J, Li M, Cao P, Zhao J, et al: Multi-omics and
pharmacological characterization of patient-derived glioma cell
lines. Nat Commun. 15:67402024. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jiang X, Zhou X, Zhang L, Chen G, Li S and
Cao Y: Long-stranded non-coding RNA HCG11 regulates glioma cell
proliferation, apoptosis and drug resistance via the sponge
MicroRNA-144COX-2 axis. Cell Mol Biol (Noisy-le-grand). 67:62–67.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Huang X, Lin J, Wang J, Yang W, Ou W,
Huang X, Chen J, Zhang Z and Wu X: GNGT1 is a potential prognostic
and immunologic biomarker in gastric cancer. Sci Rep. 15:211492025.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Cai XX, Chen GM, Zheng ZQ, Yin YX, Wang S,
Qiao L, Chen XJ, Zhao BW, Duan JL, Liang CC, et al: Transcriptional
landscape and predictive potential of long noncoding RNAs in
peritoneal recurrence of gastric cancer. Mol Cancer. 23:2842024.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xiao S, Jiang S, Wen C, Wang H, Nie W,
Zhao J and Zhang B: EMC2 promotes breast cancer progression and
enhances sensitivity to PDK1/AKT inhibition by deubiquitinating
ENO1. Int J Biol Sci. 21:2629–2646. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mathias C, Pedroso GA, Pabst FR, de Lima
RS, Kuroda F, Cavalli IJ, de Oliveira JC, Ribeiro EMSF and Gradia
DF: So alike yet so different. Differential expression of the long
non-coding RNAs NORAD and HCG11 in breast cancer subtypes. Genet
Mol Biol. 44:e202001532021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Liu H, Li J, Koirala P, Ding X, Chen B,
Wang Y, Wang Z, Wang C, Zhang X and Mo YY: Long non-coding RNAs as
prognostic markers in human breast cancer. Oncotarget.
7:20584–20596. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Dashti S, Taherian-Esfahani Z,
Kholghi-Oskooei V, Noroozi R, Arsang-Jang S, Ghafouri-Fard S and
Taheri M: In silico identification of MAPK14-related lncRNAs and
assessment of their expression in breast cancer samples. Sci Rep.
10:83162020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yuan YX, Chen RJ, Tu GH, Li CQ, Xu LL, Lu
YL and Wu LX: The SP1-superenhancer-SPHK1 axis mediates niraparib
resistance in TNBC. Pharmaceuticals (Basel). 18:16222025.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Duan Y, Chen HL, Ling M, Zhang S, Ma FX,
Zhang HC and Lv XA: The curcumin analog EF24 inhibits proliferation
and invasion of triple-negative breast cancer cells by targeting
the long noncoding RNA HCG11/Sp1 axis. Mol Cell Biol.
42:e00163212022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Smolarz B, Biernacka K, Łukasiewicz H,
Samulak D, Piekarska E, Romanowicz H and Makowska M: Ovarian
cancer-epidemiology, classification, pathogenesis, treatment, and
estrogen receptors' molecular backgrounds. Int J Mol Sci.
26:46112025. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Jha SK, De Rubis G, Devkota SR, Zhang Y,
Adhikari R, Jha LA, Bhattacharya K, Mehndiratta S, Gupta G, Singh
SK, et al: Cellular senescence in lung cancer: Molecular mechanisms
and therapeutic interventions. Ageing Res Rev. 97:1023152024.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Li Z, Qiao W, Yu S, Fan B, Yang M, Wu M,
Qiu F and Wang J: Integrating computational pathology and
multi-transcriptomics to characterize lung adenocarcinoma
heterogeneity and prognostic modeling. Int J Surg. 111:5162–5181.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zupancic M, Näsman A, Friesland S and
Dalianis T: Adenoid cystic carcinoma, clinical presentation,
current treatment and approaches towards novel therapies.
Anticancer Res. 44:1325–1334. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Toracchio L, Carrabotta M, Mancarella C,
Morrione A and Scotlandi K: EphA2 in cancer: Molecular complexity
and therapeutic opportunities. Int J Mol Sci. 25:121912024.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Fu XP, Ji CY, Tang WQ, Yu TT and Luo L:
Long non-coding RNA LOXL1-AS1: A potential biomarker and
therapeutic target in human malignant tumors. Clin Exp Med.
24:932024. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
El-Tanani Y, El-Tanani M, Rabbani SA,
Babiker R and Satyam SM: Advancements in non-invasive biomarkers
for detection and monitoring of breast cancer recurrence. Sci Prog.
108:3685042513623502025. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bhattacharjee R, Prabhakar N, Kumar L,
Bhattacharjee A, Kar S, Malik S, Kumar D, Ruokolainen J, Negi A,
Jha NK and Kesari KK: Crosstalk between long noncoding RNA and
microRNA in cancer. Cell Oncol (Dordr). 46:885–908. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Jiang X, Qu A, Zhang S, Jin S, Wang L and
Zhang Y: RNA-seq profiling identified a three-lncRNA panel in serum
as potential biomarker for muscle-invasive bladder cancer. Front
Oncol. 14:14510092024. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Shahgaldi S, Hussen BM, Eslami S, Kiani A
and Ghafouri-Fard S: MAPK14 and its associated lncRNAs are
up-regulated in lung tumors. Sci Rep. 15:367352025. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Luo L, Yang F, Fu X, Yu T, Tang W and Xue
J: The emerging role of long non-coding RNA 01296 in human
malignancies. Curr Mol Med. 25:1010–1024. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Coan M, Haefliger S, Ounzain S and Johnson
R: Targeting and engineering long non-coding RNAs for cancer
therapy. Nat Rev Genet. 25:578–595. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Alzahrani SM, Al Doghaither HA, Al-Ghafari
AB and Pushparaj PN: 5-Fluorouracil and capecitabine therapies for
the treatment of colorectal cancer (review). Oncol Rep. 50:1752023.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Lavoro A, Ricci D, Gattuso G, Longo F,
Spoto G, Vitale ACV, Giuliana MC, Falzone L, Libra M and Candido S:
Recent advances on gene-related DNA methylation in cancer
diagnosis, prognosis, and treatment: A clinical perspective. Clin
Epigenetics. 17:762025. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zeng Z, Cheng J, Ye Q, Zhang Y, Shen X,
Cai J and Li M: A 14-methylation-driven differentially expressed
RNA as a signature for overall survival prediction in patients with
uterine corpus endometrial carcinoma. DNA Cell Biol. 39:975–991.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zhang Y, Zhang X, Zhu H, Liu Y, Cao J, Li
D, Ding B, Yan W, Jin H and Wang S: Identification of potential
prognostic long non-coding RNA biomarkers for predicting recurrence
in patients with cervical cancer. Cancer Manag Res. 12:719–730.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Wu S, Zhong B, Yang Y, Wang Y and Pan Z:
ceRNA networks in gynecological cancers progression and resistance.
J Drug Target. 31:920–930. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Ren S, Lee W, Park B and Han K:
Constructing lncRNA-miRNA-mRNA networks specific to individual
cancer patients and finding prognostic biomarkers. BMC Genom Data.
25 (Suppl 1):S672024. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Tan YT, Lin JF, Li T, Li JJ, Xu RH and Ju
HQ: LncRNA-mediated posttranslational modifications and
reprogramming of energy metabolism in cancer. Cancer Commun (Lond).
41:109–20. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Lee S, Rauch J and Kolch W: Targeting MAPK
signaling in cancer: Mechanisms of drug resistance and sensitivity.
Int J Mol Sci. 21:11022020. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Papoutsoglou P and Morillon A:
Extracellular vesicle lncRNAs as key biomolecules for cell-to-cell
communication and circulating cancer biomarkers. Noncoding RNA.
10:542024.PubMed/NCBI
|
|
82
|
Raigani M, Eftekhari Z, Adeli A and
Kazemi-Lomedasht F: Advancing gene editing therapeutics: Clinical
trials and innovative delivery systems across diverse diseases. Mol
Ther Nucleic Acids. 36:1026662025. View Article : Google Scholar : PubMed/NCBI
|
